Showing results (301-310 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.
ESMO Open|November 12, 2025
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)F Spada, F Gelsomino, M Rinzivillo, et al.
ESMO Open|December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomasD M Filippini, B Cabarrou, C Dupain, et al.
ESMO Open|January 6, 2026
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE studyS Peters, R J-B Salomonsen, I Diaz Perez, et al.
ESMO Open|December 30, 2025
Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitorsQ Vanderbecq, R Cohen, M Camus, et al.
ESMO Open|December 30, 2025
A multiomic framework for predicting laryngo-esophageal dysfunction following induction chemotherapy in hypopharyngeal-laryngeal carcinomaD Mattavelli, M Compagnoni, S Calza, et al.
ESMO Open|November 13, 2025
Access to anticancer and orphan medicines through compassionate use programs and named patient basis in seven European countriesN Rosenberg, H C Post, T Schutte, et al.
ESMO Open|October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trialM V Dieci, G Bisagni, S Bartolini, et al.
ESMO Open|May 17, 2025
Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastomaS T C Shepherd, C Kelly-Morland, S Drage, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Pageof 184